West Virginia.

Moderate

West Virginia telemedicine practice is comparatively permissive: W. Va. Code § 30-3-13a lets a prescriber establish the physician-patient relationship and e-prescribe via synchronous telemedicine (real-time audio-video, with audio-only permitted), though prescribing based solely on an online questionnaire is not an acceptable standard of care. On compounding, the Board of Pharmacy's Statement Concerning Semaglutide Compounding (2023) holds that pharmacies generally may not compound semaglutide as a copy of a commercial product and prohibits salt forms and 'research use only' API, warning of possible FDA and Board enforcement. As with New Jersey, that statement restates federal 503A policy as guidance rather than a distinctive state rule, and no documented enforcement pattern was found.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

West Virginia Medical Board

https://wvbom.wv.gov/ ↗

Pharmacy board

West Virginia Board of Pharmacy

https://www.wvbop.com/ ↗

TPC notes

Telehealth

W. Va. Code § 30-3-13a permits establishing the relationship and e-prescribing via synchronous telemedicine (real-time audio-video preferred; real-time audio-only allowed), but bars prescribing based solely on an online questionnaire and applies the in-person standard of care, with added limits on controlled substances.

Compounding

The Board of Pharmacy's 2023 semaglutide statement (citing FDCA § 503A and W. Va. Code § 30-1-1a) says semaglutide generally may not be compounded as a copy of a commercial product and prohibits salt forms, non-pharmaceutical-grade API, and 'research use only' API — echoing federal policy rather than adding a distinctive state rule.

Sources

← Back to state map